![J&J Withdraws Power Morcellators, Citing Risk of Disseminating Cancer](https://cdn.cancerletter.com/media/2024/01/05040953/40-31-gynecare-morcellex.jpg)
![J&J Withdraws Power Morcellators, Citing Risk of Disseminating Cancer](https://cdn.cancerletter.com/media/2024/01/05040953/40-31-gynecare-morcellex.jpg)
Cover Story
Free
Ethicon, the Johnson & Johnson subsidiary that manufactures nearly three-quarters of laparoscopic power morcellators on the market, has requested a withdrawal of the controversial devices.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch